Sickle cell disease
Sickle cell disease (SCD), also simply called sickle cell, or sickle cell is a group of inherited -related blood disorders. The most common type is known as sickle cell . Sickle cell anaemia results in an abnormality in the oxygen-carrying found in red blood cells. This leads to the red blood cells adopting an abnormal sickle-like shape under certain circumstances. With this shape, they cannot deform as they pass through , causing blockages.
Underlined words are explained — tap any of them.
Symptoms — what it feels like
- ·Attacks of pain, , swelling in the hands and feet, ,
Causes — why it happens
- ·: inherited gene
How it's found
- ·Blood test
Treatment
- ·Vaccination, , high fluid intake, folic acid supplementation, pain medication, blood
Complications
- · pain, , aseptic bone , , leg , priapism, , vision problems, kidney problems
Outlook
- ·Life expectancy 40–60 years (developed world)
How common each gene variant is, by ancestry
The share of people carrying the effect version of each variant. South Asian is highlighted; where it differs from European, a risk model built on Europeans can misread it.
Effect-allele frequencies. All-India is the pooled large-sample number from GenomeIndia (≈10,000 Indian genomes); the South-Asian row is the smaller 1000 Genomes phase-3 panel, kept for finer per-subpopulation resolution.
The sections below are general education drawn from public guidelines (NHS, Mayo, CPIC, WHO, ICMR). They are not individually reviewed by a clinician and are not medical advice — always talk to a doctor about your own health.
When to see a doctor
See a doctor if you or your child have repeated episodes of pain in the bones, joints, chest, or tummy, frequent infections, ongoing tiredness or pale skin, or yellowing of the eyes. If sickle cell runs in either partner's family, ask about carrier testing before starting a family.
Get emergency care for sudden severe pain, chest pain or trouble breathing, a high fever, sudden weakness, trouble speaking, a painful long-lasting erection, or a fast-growing swollen belly. These can be serious sickle-cell emergencies.
General guidance, not a diagnosis. When in doubt, see a doctor.
Questions to ask your doctor
- ?Which blood test confirms this?
- ?How can we prevent and manage pain episodes?
- ?Which infections should we guard against, and how?
- ?What are the emergency warning signs for us?
- ?Are my partner and I carriers, and what does it mean for children?
- ?Which specialists and regular checks will we need?
What to note before your visit
- ·how often pain episodes happen and what triggers them
- ·any fevers, infections, or hospital visits
- ·family history of sickle cell
- ·current medicines you take
Myths vs facts
Across the other high- (india) gene set (), 5 -'' are actually seen in South Asians () - many European-absent and still clinically 'uncertain'. For sickle cell disease, that's a pool of computationally-damaging, India-relevant, clinically-unresolved variants no one has systematically characterised.
A study that would help: Take the South-Asian-observed, European-absent, ClinVar-uncertain in and them for sickle cell disease: functional or family segregation to move them from 'uncertain' to a real call. Each is a usable diagnostic result.
A national mission, a tribal burden, and a milder Indian form the textbooks learned from Africa
Sickle cell disease in India is concentrated in tribal communities — around 1 in 86 births in parts of central India, where up to 20% of affected children die before their second birthday. India launched a National Sickle Cell Elimination Mission in 2023; by late 2024 it had screened over 42 million people and identified more than 160,000 with the disease and over a million .
The Indian sickle gene sits on the 'Arab-Indian' haplotype, which raises and makes the disease clinically milder than the African forms most textbooks describe. Treatment and counselling calibrated to African severity can misjudge the Indian course. And because the is tribal, the urban South-Asian samples in global reference panels () largely miss these populations.
Carrier rates and the haplotype are documented, and the national mission is building at scale. The gap is depth on the tribal populations themselves — the modifiers of severity ( genes, co-inherited ) that would let counselling predict who runs a mild versus a severe course.
In tribal cohorts, map the modifiers (BCL11A / HBS1L-MYB , status) that separate mild from severe Indian sickle disease — turning a result into a .
- Casting light on the national mission to eliminate sickle cell disease in India, PMC 2024 ↗
- Sickle cell disease in Indian tribal population: multi-centre SCD registry, Blood Cells Mol Dis 2024 ↗
- D2I2 rare-pathogenic South-Asian scan (HBB); tribal-sampling gap is itself a flagged whitespace